Although anti-PD-1 inhibitors have been approved as standard treatment options for advanced NSCLC, their efficacy in patients harboring targetable sensitive mutations such as EGFR or ALK has not been identified. This evidence concerns the gene EGFR and non-small cell lung carcinoma.